Inogen (NASDAQ:INGN) Stock Price Passes Above Fifty Day Moving Average - What's Next?

Inogen, Inc (NASDAQ:INGN - Get Free Report)'s share price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $6.65 and traded as high as $7.50. Inogen shares last traded at $7.42, with a volume of 247,505 shares.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on INGN shares. Needham & Company LLC raised Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 target price for the company in a research report on Thursday, May 22nd. B. Riley began coverage on Inogen in a research note on Monday, June 16th. They issued a "buy" rating and a $14.00 price target for the company. Finally, Stifel Nicolaus lowered their price objective on Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a research report on Thursday, May 8th.

Inogen Price Performance

The company's 50-day moving average price is $6.65 and its two-hundred day moving average price is $8.08. The company has a market capitalization of $194.66 million, a price-to-earnings ratio of -6.30 and a beta of 1.66.

Inogen (NASDAQ:INGN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.27. Inogen had a negative return on equity of 14.76% and a negative net margin of 8.08%. The firm had revenue of $82.28 million during the quarter, compared to analyst estimates of $79.57 million. On average, equities research analysts expect that Inogen, Inc will post -1.73 EPS for the current fiscal year.

Hedge Funds Weigh In On Inogen

Institutional investors have recently added to or reduced their stakes in the business. Tudor Investment Corp ET AL grew its position in shares of Inogen by 44.9% during the 4th quarter. Tudor Investment Corp ET AL now owns 82,852 shares of the medical technology company's stock worth $760,000 after buying an additional 25,681 shares during the period. GAMMA Investing LLC boosted its stake in Inogen by 5,738.9% during the first quarter. GAMMA Investing LLC now owns 5,547 shares of the medical technology company's stock worth $400,000 after acquiring an additional 5,452 shares in the last quarter. Bank of America Corp DE grew its holdings in Inogen by 2.7% in the fourth quarter. Bank of America Corp DE now owns 127,326 shares of the medical technology company's stock worth $1,168,000 after purchasing an additional 3,304 shares during the period. Dimensional Fund Advisors LP grew its holdings in Inogen by 25.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company's stock worth $5,574,000 after purchasing an additional 123,208 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Inogen by 23.5% in the fourth quarter. Bank of New York Mellon Corp now owns 126,461 shares of the medical technology company's stock valued at $1,160,000 after purchasing an additional 24,082 shares in the last quarter. 89.94% of the stock is owned by institutional investors and hedge funds.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.